Table 2.
Demographic and clinical characteristics of patients whose data were extracted from medical records
| Patient characteristics | Patient data reported by physicians categorized into three groups | Total sample [N = 1096] |
F-value (p-value)/p-valuea | Pairwise comparisonsb | ||
|---|---|---|---|---|---|---|
| Group 1: diabetes specialists [N = 437] |
Group 2: GPwSIs [N = 216] |
Group 3: GPs [N = 443] |
||||
| Age at the time of survey completion [mean (SD)] | 52.8 (11.2) | 55.4 (11.1) | 57.3 (12.1) | 55.1 (11.7) | 16.65 (< 0.0001) |
A: 0.0309 B: < 0.0001 C: 0.1267 |
| Age at the time of diagnosis [mean (SD)] | 45.6 (10.7) | 48.1 (11.5) | 48.2 (11.5) | 47.1 (11.3) | 6.92 (0.0010) |
A: 0.0294 B: 0.0026 C: 0.9897 |
| Age at GLP-1 RA initiation [mean (SD)] | 52.6 (11.1) | 55.1 (11.1) | 57.1 (12.1) | 54.9 (11.7) | 17.00 (< 0.0001) |
A: 0.0307 B: < 0.0001 C: 0.1150 |
| Sex [n (%)] | 0.2422 | |||||
| Male | 244 (55.8) | 109 (50.5) | 254 (57.3) | 607 (55.4) | ||
| Female | 193 (44.2) | 107 (49.5) | 189 (42.7) | 489 (44.6) | ||
| Patient’s ethnic/racial origin [n (%)] | 0.1031c | |||||
| White | 331 (75.7) | 140 (64.8) | 311 (70.2) | 782 (71.4) | ||
| African/Black | 19 (4.3) | 19 (8.8) | 22 (5.0) | 60 (5.5) | ||
| Asian or Pacific Islander | 17 (3.9) | 15 (6.9) | 28 (6.3) | 60 (5.5) | ||
| North Africa and Middle Eastern | 7 (1.6) | 5 (2.3) | 7 (1.6) | 19 (1.7) | ||
| Indian subcontinent (Indian, Pakistani, Bangladeshi) | 59 (13.5) | 35 (16.2) | 71 (16.0) | 165 (15.1) | ||
| Other | 2 (0.5) | 1 (0.5) | 2 (0.5) | 5 (0.5) | ||
| Do not know | 2 (0.5) | 1 (0.5) | 2 (0.5) | 5 (0.5) | ||
| BMI [mean (SD)] | 35.7 (6.1) | 34.6 (5.9) | 35.1 (6.1) | 35.2 (6.0) | 1.97 (0.1399) | |
| Comorbidities at the time of GLP-1 RA initiation [n (%)] | ||||||
| Congestive heart failure | 13 (3.0) | 8 (3.7) | 7 (1.6) | 28 (2.6) | 0.2075 | |
| Cardiovascular disease | 153 (35.0) | 49 (22.7) | 121 (27.3) | 323 (29.5) | 0.0022 | |
| Cardiovascular disease—microvascular complications | 95 (21.7) | 33 (15.3) | 57 (12.9) | 185 (16.9) | 0.0016 | |
| Cardiovascular disease—macrovascular complications | 86 (19.7) | 21 (9.7) | 78 (17.6) | 185 (16.9) | 0.0053 | |
| Liver disease | 54 (12.4) | 22 (10.2) | 29 (6.5) | 105 (9.6) | 0.0130 | |
| Obesity | 406 (92.9) | 174 (80.6) | 362 (81.7) | 942 (85.9) | < 0.0001 | |
| Renal disease | 70 (16.0) | 40 (18.5) | 68 (15.3) | 178 (16.2) | 0.5775 | |
| Patient had none of the above comorbidities | 18 (4.1) | 28 (13.0) | 48 (10.8) | 94 (8.6) | < 0.0001 | |
BMI body mass index, GLP-1 glucagon-like peptide-1, GPwSIs general practitioners with a special interest in diabetes, GPs general practitioners with no special interest in diabetes, RA receptor agonist, SD standard deviation, ANOVA analysis of variance
aFor continuous variables, F- and p-values from ANOVAs comparing the three groups are presented. For categorical variables, p-values from Chi-square tests are presented
bPairwise comparisons with Scheffe’s adjustment were conducted when the overall ANOVA model was statistically significant: A: group 1 vs. group 2; B: group 1 vs. group 3; C: group 2 vs. group 3
cExcluding the ‘other’ and ‘don’t know’ groups